30 novembre 2018 | International,

Reinventing Drug Discovery and Development for Military Needs

Flying at 50,000 feet, diving deep in the ocean, or hiking for miles with gear through extreme climates, military service members face conditions that place unique burdens on their individual physiology. The potential exists to develop pharmacological interventions to help service members complete their toughest missions more safely and efficiently, and then recover more quickly and without adverse effects, but those interventions must work on complex physiological systems in the human body. They will not be realized under the prevailing system of drug discovery and development with its focus on engaging single molecular targets. DARPA created the Panacea program to pursue the means of rapidly discovering, designing, and validating new, multi-target drugs that work with the body's complexity to better support the physiological resilience and recovery of military service members.

The premise of Panacea is that the physiological systems of the human body work in complex and highly integrated ways. Drugs exert effects on our bodies by physically interacting with and changing the functional state of biomolecules that govern the functions of cells and tissues. Most drugs target proteins, which are the principle cellular workhorses. Ideally, drugs would target multiple proteins simultaneously to exert precise, network-level effects.

One major problem facing the drug development community is that the functional proteome — the complete collection of proteins and their roles in signaling networks — is largely dark to science. Despite being able to identify many of the proteins within a cell, researchers do not have a firm grasp on everything those proteins do and how they interact to affect physiology.

Due to this sparsity of structural and functional knowledge, the state of the art in drug development — what Panacea seeks to transform — is to engage only a very small fraction of known protein targets to achieve an effect. In fact, today's approach to drug design singles out individual proteins in certain cells. That hyper-specificity is an attempt to minimize the risk of side effects and speed time to market, but it also yields a thin stream of drugs, many of which have similar mechanisms and relatively muted effectiveness compared to what might be achieved using a multi-target, systems-based approach.

“The current roster of drugs approved by the U.S. Food and Drug Administration only targets about 549 proteins, yet the body can produce more than six million different protein variants,” said Tristan McClure-Begley, the Panacea program manager. “The opportunity space for pharmacological intervention is vast and effectively untapped, but to access it we need new technology for understanding and targeting the human functional proteome.”

Panacea will address the lack of functional knowledge about the proteome. DARPA's call to the research community is to consider complex physiological conditions relevant to military service members — for instance, metabolic stress during extreme endurance missions or pain and inflammation after injury; investigate the molecular mechanisms underlying those conditions; identify multiple, key molecular targets involved; and develop novel medicinal chemistry approaches to synthesize interventions that modulate those targets. DARPA believes that multi-target drugs will deliver safer and more efficacious solutions to military requirements for readiness and recovery over state-of-the-art interventions.

“Many of the most successful drugs produced in the past were found rather than made, and we knew what they did long before we knew how they did it,” McClure-Begley said. “To deliver improved interventions, we need to get to a place where we can investigate all of the potential proteins at play for a given condition and then prioritize sets of protein targets and signaling networks to effectively modulate physiological systems, regardless of what prior knowledge exists about those targets.”

The Panacea program aims to generate initial proof of concept for this new direction in drug discovery and development. Research will primarily involve animal models, human cell derived organoids, and high-throughput cell culture models. However, to support eventual transition to humans, DARPA will work with federal agencies to develop a regulatory pathway for future medical use. By the end of the five-year program, DARPA will require teams to submit novel drug candidates to the U.S. Food and Drug Administration for review as an Investigational New Drug or for Compassionate Use.

DARPA will hold a Proposers Day on December 14, 2018, in Arlington, Virginia, to provide more information about Panacea and answer questions from potential proposers. For details of the event, including registration requirements, visit https://go.usa.gov/xP6hD.

A forthcoming Broad Agency Announcement will fully describe the program structure and objectives.

https://www.darpa.mil/news-events/2018-11-28

Sur le même sujet

  • DSEI: UK’s Warrior fleet upgrade about 18 months away from kickoff

    12 septembre 2019 | International, Terrestre

    DSEI: UK’s Warrior fleet upgrade about 18 months away from kickoff

    By: Andrew Chuter LONDON — Negotiations are underway on a production contract to update the British Army's fleet of Warrior infantry fighting vehicles, according to the Ministry of Defence official running the program. “We are now talking about how we go forward on production,” Marcus Bruton, the MoD's Warrior upgrade director said during an interview at the DSEI show Sept. 10. Bruton said the two sides were probably 18 months away from a contract allowing Lockheed Martin and its supply chain to start upgrading the Warrior. The effort to progress the long running Warrior capability sustainment development program into the manufacturing phase has come on the back of Lockheed Martin successfully achieving 20 battlefield mission assessments – a key milestone in the reliability growth test program now underway. The MoD said in March it would open manufacturing contract negotiations once it was satisfied with progress on reliability trials. In late August Lockheed Martin achieved that milestone. The company said that in cooperation with the British Army Armoured Trials and Development Unit, it had fired thousands of rounds from the new CTAI developed 40 mm cannon, driven more than 5,000 kms, and achieved the battlefield mission assessments with flying colors. Lockheed Martin Warrior program Director Lee Fellows said he is expecting a deal towards the back end of next year. The company is keen to get the production contract signed and sealed but “we need to get it right, so it will take as long as it needs to," he added. "Getting it done at pace and quality aequally important.” Quantities, the mix of variants and affordability are among the items due to be discussed. Discussions on how to overcome issues of design authority ownership is also part of the build up to a production contract, said the officials. BAE holds the design authority on the existing legacy Warrior, but Lockheed Martin holds the approval for the extensive upgrade — particularly the new turret. “The expectation is there will be a collaboration with BAE. We are talking with them already, that's part of the negotiations,” said Fellows. Neither executive will comment on what sort of upgrade numbers the British Army is looking at. Roughly 740 vehicles were delivered to the British Army starting 1988 but a number were lost in Iraq and Afghanistan. A number of vehicles have been earmarked for battlefield support duties that don't require a new turret. At one time the number of hulls to be updated was in the region of 380, but suppliers at a company briefing in March said that as the British Army downsized and budgets became more challenging the figure slipped to around 265 or lower. The Lockheed Martin executive said that the next 18 months or so will bring further reliability growth trials, but that the major risks have been removed and testing had not unearthed any significant problems. The update is considered one of the Army's top priorities alongside other vehicle programs, including the Challenger 2 tank upgrade and procurement of the Boxer mechanized infantry vehicle from German company Artec. Lockheed Martin was awarded a development deal to upgrade Warrior vehicles back in 2011, but the program has been dogged with problems slowing down progress towards a production deal by several years. The update program includes a new turret fitted with the CTAI cannon, electronic architecture, a modular protection systems and other enhancements. It's a much needed update. The current vehicle's inability to fire on the move is just one of a number of shortcomings deemed to make the Warrior obsolete by current battlefield standards. https://www.defensenews.com/digital-show-dailies/dsei/2019/09/11/uks-warrior-fleet-upgrade-about-18-months-away-from-kickoff

  • Elbit Systems Awarded $35 Million to Equip Montenegro’s 4X4 Vehicles with Remote Control Weapon Stations

    18 décembre 2019 | International, Terrestre, C4ISR

    Elbit Systems Awarded $35 Million to Equip Montenegro’s 4X4 Vehicles with Remote Control Weapon Stations

    Haifa, Israel, December 16, 2019 – Elbit Systems Ltd. (NASDAQ:ESLT and TASE: ESLT) ("Elbit Systems") announced today that following a contract signed between the Israeli Ministry of Defense and the Ministry of Defense of Montenegro, it was awarded approximately $35 million to supply the Montenegrin Armed Forces with Remote Controlled Weapon Stations (“RCWS”) for the new Oshkosh Defense (“Oshkosh”) 4X4 Joint Light Tactical Vehicles (“JLTV”). In this contract Elbit Systems will perform full integration of the RCWS onboard, the JLTV over a three-year period and will provide logistic support for a seven-year period. Elbit Systems 12.7mm RCWS is lightweight, low silhouette, dual axis and stabilized, mounted externally onboard armored vehicles. The RCWS offers accurate firing on-the-move and is operated via handles and Smart Displays by the gunner from within the vehicle, providing full protection for the vehicles' crew who are safely located inside. Yehuda (Udi) Vered, General Manager of Elbit Systems Land, commented: “We are very proud to introduce our RCWS to Montenegro's Armed Forces. This recent award further expands our NATO customer base and strengthens our growing cooperation with Oshkosh. We are witnessing a growing demand worldwide for our RCWS, of which many hundreds are already operational onboard a range of land and naval platforms, and we trust that further customers will follow in acquiring our advanced and mature weapon stations”. About Elbit Systems Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land, and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance ("C4ISR"), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios and cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems. For additional information, visit: [elbitsystems.com]elbitsystems.com, follow us on Twitter or visit our official Youtube Channel. This press release contains forward‑looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current fact. Forward-looking statements are based on management's expectations, estimates, projections and assumptions. Forward‑looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results, performance and trends may differ materially from these forward‑looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; and the outcome of legal and/or regulatory proceedings. The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.'s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward‑looking statements speak only as of the date of this release. The Company does not undertake to update its forward-looking statements. Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies. All other brand, product, service and process names appearing are the trademarks of their respective holders. Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein. Visit our Press Relations website for background materials and information regarding Elbit Systems fields of activity. David Vaaknin Vice President, Head of Corporate Communications Tel: 972-77-2946691 Cell: 972-52-8000403 E-Mail: david.vaaknin@elbitsystems.com Dana Tal-Noyman Manager International Corporate Communications Tel: 972-77-294-8809 Cell: 972-54-9998809 E-Mail: dana.tal@elbitsystems.com https://www.epicos.com/article/521991/elbit-systems-awarded-35-million-equip-montenegros-4x4-vehicles-remote-control-weapon

  • Croatian lawmakers back new armored vehicles, Spike anti-tank missiles

    20 mars 2023 | International, Terrestre

    Croatian lawmakers back new armored vehicles, Spike anti-tank missiles

    The country wants new vehicles and weapons to meet capability targets pledged to NATO.

Toutes les nouvelles